RIPK1: A rising star in inflammatory and neoplastic skin diseases

Liping Jin; Panpan Liu; Mingzhu Yin; Mi Zhang; Yehong Kuang; Wu Zhu

doi:10.1016/j.jdermsci.2020.06.001

RIPK1: A rising star in inflammatory and neoplastic skin diseases

J Dermatol Sci. 2020 Sep;99(3):146-151. doi: 10.1016/j.jdermsci.2020.06.001. Epub 2020 Jun 11.

Authors

Liping Jin¹, Panpan Liu¹, Mingzhu Yin¹, Mi Zhang¹, Yehong Kuang², Wu Zhu³

Affiliations

¹ Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha, China.
² Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha, China. Electronic address: [email protected].
³ Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha, China. Electronic address: [email protected].

PMID: 32600738
DOI: 10.1016/j.jdermsci.2020.06.001

Abstract

Skin diseases bring great psychological and physical impacts on patients, however, a considerable number of skin diseases still lack effective treatments, such as psoriasis, systemic lupus erythematosus, melanoma and so on. Receptor-interacting serine threonine kinase 1 (RIPK1) plays an important role in cell death, especially necroptosis, associated with inflammation and tumor. As many molecules modulate the ubiquitination of RIPK1, disruption of this checkpoint can lead to skin diseases, which can be ameliorated by RIPK1 inhibitors. This review will focus on the molecular mechanism of RIPK1 activation in inflammation as well as the current knowledges on the contribution of RIPK1 in skin diseases.

Keywords: Inflammation; Melanoma; Psoriasis; RIPK1; Skin disease; Systemic lupus erythematosus.

Publication types

Review

MeSH terms

Animals
Clinical Trials, Phase II as Topic
Dermatitis / drug therapy
Dermatitis / genetics
Dermatitis / immunology*
Dermatitis / pathology
Disease Models, Animal
Drug Evaluation, Preclinical
Half-Life
Humans
Imidazoles / pharmacology
Indoles / pharmacology
Mice
Mice, Knockout
Necroptosis / drug effects
Necroptosis / genetics
Necroptosis / immunology*
Oxazepines / pharmacology
Oxazepines / therapeutic use
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use*
Rats
Receptor-Interacting Protein Serine-Threonine Kinases / antagonists & inhibitors
Receptor-Interacting Protein Serine-Threonine Kinases / genetics
Receptor-Interacting Protein Serine-Threonine Kinases / metabolism*
Signal Transduction / drug effects
Signal Transduction / genetics
Signal Transduction / immunology
Skin / drug effects
Skin / immunology
Skin / pathology
Skin Neoplasms / drug therapy
Skin Neoplasms / genetics
Skin Neoplasms / immunology*
Skin Neoplasms / pathology
Treatment Outcome
Triazoles / pharmacology
Triazoles / therapeutic use
Tumor-Associated Macrophages / drug effects
Tumor-Associated Macrophages / immunology
Tumor-Associated Macrophages / metabolism
Ubiquitination / immunology

Substances

GSK2982772
Imidazoles
Indoles
Oxazepines
Protein Kinase Inhibitors
Triazoles
necrostatin-1
RIPK1 protein, human
Receptor-Interacting Protein Serine-Threonine Kinases
Ripk1 protein, mouse